Archives
|
Entry
|
Blogger
|
Date
|
Location
|
|
Amylin Forms Global Alliance in Obesity Drug Development; TEDMED’s Show Will Go On, Sequenom Sued for Civil Fraud, & More San Diego Biotech News
|
Bruce V. Bigelow |
11/05/09 |
San Diego
|
|
Amylin Strikes $1 Billion Deal with Takeda to Co-Develop Weight Loss Drugs
|
Luke Timmerman |
11/02/09 |
San Diego
|
|
Amylin, Lilly’s Byetta Wins FDA Approval as Standalone Therapy, Without Combo Drugs
|
Luke Timmerman |
10/30/09 |
San Diego
|
|
Novocell Gets $20 Million Award
|
Denise Gellene |
10/29/09 |
San Diego
|
|
Diabetes drug from San Diego’s Amylin caught up in Aussie Brouhaha
|
Denise Gellene |
10/27/09 |
San Diego
|
|
Eastbourne Dumps Amylin Shares, Illumina Inks Licensing Deal, Avanir Releases Pseudobulbar Affect Data, & More San Diego Life Sciences News
|
Denise Gellene |
10/15/09 |
San Diego
|
|
Eastbourne Capital Dumps Entire Stake in Amylin After Partial Victory in Proxy Battle
|
Luke Timmerman |
10/09/09 |
San Diego
|
|
Amylin CEO, Putting Boardroom Coup Behind Him, Turns Up Heat on New Diabetes Drug
|
Luke Timmerman |
09/29/09 |
San Diego
|
|
It’s About Health Care, Not Health Insurance
|
Norm Wu |
09/28/09 |
Seattle
|
|
Lee Hood’s New Idea, Calypso Scores $50M, Novo’s Historic Mistake Pays Off for Seattle, & More Seattle-Area Life Sciences News
|
Luke Timmerman |
09/25/09 |
Seattle
|
|
Novo Nordisk’s Historic Mistake is Seattle’s Future Gain, Says Novo CEO
|
Luke Timmerman |
09/18/09 |
Seattle
|
|
Amylin, Dark Horse of the Obesity Drug Battle, Follows Fast Behind Arena, Orexigen
|
Luke Timmerman |
09/14/09 |
San Diego
|
|
Arena Eagerly Awaits Answer to $1 Billion Question: Does It Have a Big-Time Obesity Drug?
|
Luke Timmerman |
09/08/09 |
San Diego
|
|
Ailing Metabasis Hires Advisory Firm
|
Bruce V. Bigelow |
09/03/09 |
San Diego
|
|
Orexigen Aims to Redefine Obesity, as Amgen Vet Revamps Company to Compete
|
Luke Timmerman |
09/02/09 |
San Diego
|
|
Amylin and Biogen Idec Make Board Changes, Inovio Catches Wave of Investor ‘Swine Flu’ Fervor, Ligand Buys Neurogen, & Other San Diego Life Sciences News
|
Bruce V. Bigelow |
08/27/09 |
San Diego
|
|
Former Novartis CEO Elected as Amylin Chairman
|
Bruce V. Bigelow |
08/25/09 |
San Diego
|
|
In Aftermath of Proxy Fight Amylin Pharmaceuticals Investor Expresses Concern Over Empty Board Chair Seat
|
Bruce V. Bigelow |
08/07/09 |
San Diego
|
|
Protecting America’s Leadership in Biotech Discovery
|
James N. Thomas |
08/06/09 |
Seattle
|
|
Former CEO Alexis Borisy Voices Mixed Feelings on CombinatoRx Saga
|
Ryan McBride |
07/06/09 |
Boston
|
|
Documents Shed Light on Cam Garner’s Stealth Venture
|
Denise Gellene |
06/26/09 |
San Diego
|
|
Anadys Cuts Jobs, Obesity Drug Developers Show Intriguing Results, Trius Antibiotic Passes Key Test, & More San Diego Life Sciences News
|
Bruce V. Bigelow |
06/11/09 |
San Diego
|
|
Amylin’s Would-Be Savior, Once-Weekly Diabetes Shot, Shows Two-Year Benefit
|
Luke Timmerman |
06/07/09 |
San Diego
|
|
Novocell Snaps Up Second Stem Cell Patent, New CEO Pursues “Next Big Field” of Biotech
|
Luke Timmerman |
06/03/09 |
San Diego
|
|
Amylin Founder Ted Greene, In Exclusive Interview, Upbeat About Outcome of Proxy Battle
|
Bruce V. Bigelow |
06/02/09 |
San Diego
|
|
Amylin Chairman, Lead Director Ousted as Dissidents Gain Two Board Seats
|
Luke Timmerman |
06/02/09 |
San Diego
|
|
Amylin Pharmaceuticals Gets New Directors (But Who Are They?), Ophthonix and Vical Raise Capital, Metabasis Cuts Back—Again, & More San Diego Life Sciences News
|
Bruce V. Bigelow |
05/28/09 |
San Diego
|
|
Amylin’s Dissident Shareholders Gain Influence on Board
|
Bruce V. Bigelow |
05/27/09 |
San Diego
|
|
Latest Metabasis Cutbacks Leave Just Seven Employees
|
Juha-Pekka Tikka |
05/27/09 |
San Diego
|
|
CombinatoRx Diabetes Drug Shows Promise
|
Ryan McBride |
05/27/09 |
Boston
|
|
Page 1 of
4 |
next page » |
Business, life sciences, and technology news — covering Boston, Seattle, San Diego, and beyond.
© 2007-2009, Xconomy, Inc.
XCONOMY is a registered service mark of Xconomy, Inc.
All rights reserved.
Site designed by
Matthew Bouchard, produced by
Andrew Koyfman,
and powered by WordPress.
